Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PolyCore PUF in Cardio Renal Syndrome
NCT03994874Phase 2Recruiting
- Sponsor
- Iperboreal Pharma
- Start
- Apr 2025
- Primary completion
- Dec 2026
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in heart failure with reduced ejection fraction (HFrEF) (2 arms), sponsored by Iperboreal Pharma. Primary endpoint: Composite end-point of mortality and worsening patient's condition at 7 months. Started Apr 2025; status: recruiting.
02
Conditions
heart failure with reduced ejection fraction (HFrEF)
Beyond the preview
Go deeper on NCT03994874.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03994874.